Hydroquinone

Hydroquinone was first isolated by Wöhler in 1844 and has since become one of the more versatile industrial chemicals, serving as a photographic developer, rubber antioxidant, polymerization inhibitor, and pharmaceutical intermediate. [1] Its ability to inhibit the enzyme tyrosinase — which catalyzes the production of melanin in skin — was recognized in the mid-20th century, leading to its widespread adoption as a skin-lightening agent in cosmetics marketed for treating hyperpigmentation, melasma, and freckles. By the 1970s, 2–4% hydroquinone creams were among the most commonly used dermatological treatments globally, particularly in countries where lighter skin tone is socially valorized. [2] However, concerns about toxicity accumulated. Animal studies found that high oral doses cause kidney damage, liver toxicity, and ultimately carcinogenicity — the NTP found clear evidence of renal tubule carcinomas in male rats and some evidence of other tumors in rodents. The EPA classified it as a Group B2 probable human carcinogen. Beyond cancer, prolonged skin use can paradoxically cause exogenous ochronosis — a permanent bluish-black discoloration of the treated skin — particularly in darker-skinned individuals and in African countries. [3] The EU, Japan, Australia, and many other jurisdictions banned or restricted hydroquinone in cosmetics. The FDA proposed banning it from over-the-counter products in 2006 but never finalized the rule, leaving it in a regulatory limbo in the US market. Industrial exposures continue from photographic processing, rubber manufacturing, and pharmaceutical production facilities.

Cosmetic use is the primary route for the general population — applying skin-lightening creams containing hydroquinone results in dermal absorption; the compound readily penetrates skin. Industrial workers are exposed through inhalation of dusts or vapors during manufacturing of rubber products, photographic chemicals, and pharmaceuticals. Dietary exposure from foods is minimal but measurable, as hydroquinone occurs naturally as a metabolite of arbutin found in some plants (wheat, coffee, tea).

Hydroquinone is metabolized to reactive semiquinone and benzoquinone species that can alkylate proteins and DNA. Chronic kidney damage (nephropathy) is a well-documented effect in animals and occupationally exposed individuals. The EPA-classified probable carcinogenicity is based on renal carcinomas in male rats. Benzene, a known human carcinogen, is metabolized partly to hydroquinone — the latter is thought to contribute to benzene's bone marrow toxicity and leukemogenicity. Long-term topical use can cause ochronosis, a disfiguring dermal condition. Systemic absorption from topical application can cause systemic effects including nausea and headache.

People using hydroquinone-containing skin lightening products represent the largest exposed population globally — particularly prevalent in sub-Saharan Africa, Southeast Asia, and among immigrant communities in Western countries. Rubber and photographic processing workers face occupational exposures. Laboratory chemists handling the compound without adequate controls are also at risk.

1. Discontinue use of hydroquinone-containing skin-lightening products — alternatives such as kojic acid, azelaic acid, niacinamide, vitamin C, and tranexamic acid have evidence for managing hyperpigmentation with better safety profiles. 2. Check cosmetic ingredient lists for hydroquinone or its masked forms (tocopheryl acetate is different, but arbutin metabolizes to hydroquinone). 3. Industrial workers should use local exhaust ventilation and wear nitrile gloves and eye protection when handling hydroquinone. 4. Consult a dermatologist before using any prescription-strength skin-lightening treatments. 5. If you notice darkening or discoloration of treated skin, stop use and see a dermatologist — this may be early ochronosis.